Bachelor of Chemistry, Peking University; Ph.D. in Chemistry, North Carolina State University.

With extensive experience in MNCs, Dr. Fu has held key R&D positions at Pfizer, AbbVie, and Takeda Pharmaceuticals in the U.S. Upon returning to China, he served as Head of Early Research Quality at Junshi Biosciences and CTO at Mobiomics.

Boasting over 17 years of end-to-end ADC drug development experience, he has successfully filed one BLA each in China and the U.S. (Toripalimab, Retacrit), obtained EUA for neutralizing antibodies against COVID-19. Dr. Fu also has overseen the target review and selection of 14 discovery programs, managed over 16 project milestone reviews, and successfully submitted 18 INDs in China and the U.S. He has led teams of over 120 members, empowering innovative and efficient R&D. Dr. Fu has published 20+ SCI papers in top international journals, with total citations exceeding 2,200.

Specializing in ADC Drug Design and Discovery.

With a B.S. in Chemistry from Peking University and a Ph.D. in Organic Chemistry from The University of Texas at Austin, his research interest focused on organic methodology and total synthesis, and he published multiple first-author papers in top-tier (Q1) journals.

Dr. Feng joined AbbVie and became the major contributor to the process development and evolution of globally first-in-class ADC linker-payloads, advancing two world-leading ADC programs to Phase I and II, respectively.

At DDSU of WuXi AppTec, Dr. Feng has led drug discovery and pre-clinical development of small molecule and cyclic peptide candidates. With lead discovery by precision drug design, he successfully advanced 2 programs to clinical stage, including filing a small-molecule IND in 18 months and reaching the IND milestone within the record-breaking time of 10 months from target selection in another program.

Ms. Wan brings over 20 years of hands-on experience in HR management, cross-cultural operations and team establishment with a proven record in enhancing organizational efficiency and implementing talent strategies.

Previously, she served as General Manager and Head of Operations for China at Terns Pharmaceuticals, overseeing end-to-end management of local functions including HR, procurement, legal, IT, finance, and government relations. Prior to that, she was Associate Director of HR at Novartis China, supporting marketing, sales, and drug development divisions. Her earlier career includes seven years in the automotive industry, where she specialized in setting up new R&D teams in Germany.

Ms. Wan holds a bachelor’s degree in English and Economics from Wuhan University of Technology and a postgraduate degree from HKU.